Ligand to acquire Apeiron Biologics for US$100 million

Acquisition provides Ligand with the royalty rights to QARZIBA, a highly differentiated, commercial oncology drug marketed in 35 countries by global pharmaceutical company Recordati S.p.A.

Olink announces receipt of CMA clearance for proposed acquisition by Thermo Fisher

Shares and American Depositary Shares of Olink for $26.00 per Share

Health Minister Nadda visits the AIIMS Jammu

AIIMS Jammu is a beacon of hope not only for the people of J&K, but also for that of Leh, and other neighboring states

Aster Health Academy announces strategic partnerships with premier Hospitals across India

The academy has secured partnerships with 15 esteemed hospitals

Viatris closes divestitures of OTC business

Achievement of This Major Milestone Further Simplifies and Strengthens the Company and Positions Viatris to Achieve its Key Priorities and Accelerate Future Growth

Shilpa's CDMO customer placed binding purchase order

Nephro Care India lists at 90% premium

NCIL was listed at Rs. 171 at an upper circuit premium of 90% over the fixed price band of Rs. 90

Dabur India updates on Q1 FY25

Dabur's consolidated revenue is expected to register mid to high single digit growth during Q1 FY25

Biogen completes acquisition of HI-Bio

Felzartamab demonstrated positive interim results from the Phase 2 IgA nephropathy (IgAN) study

FDA approves Roche’s Vabysmo PFS for three leading causes of vision loss

Vabysmo PFS is the first and only syringe prefilled with an FDA-approved bispecific antibody to treat retinal conditions that can cause blindness